Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Navtemadlin in p53 wild-type Merkel cell carcinoma after PD-1/PD-L1 failure or with avelumab in immunotherapy-naive disease
2020-002820-35Phase 2Terminated
- Sponsor
- Kartos Therapeutics
- Start
- Aug 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of navtemadlin and avelumab in Merkel cell carcinoma (MCC) (4 cohorts), sponsored by Kartos Therapeutics. Primary endpoints: Recommended phase 2 dose determination and Objective response rate. Started Aug 2020; status: terminated.
02
Drugs
navtemadlinavelumab
03
Conditions
Merkel cell carcinoma (MCC)
Beyond the preview
Go deeper on 2020-002820-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002820-35.